20 G vitrectomy safe and effective technique in vitreoretinal surgery

Article

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies, according to a study featured in Retina.

The retrospective study led by Dr Oriel Spierer, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Israel, reviewed the charts of 102 consecutive patients who experienced 20-gauge transconjunctival sutureless vitrectomy performed by a single surgeon.

All patients were assessed preoperatively and 1 day, 1 month and 3 months postoperatively. The main outcome measures included intraoperative/postoperative intraocular pressure and Snellen visual acuity compared to preoperative data.

Findings revealed that two patients needed suturing of 1 scleretomy due to postoperative leakage. The mean preoperative visual acuity was 1.1 ± 0.6. Three months postoperatively the mean visual acuity was 0.8 ± 0.5.

Mean preoperative intraocular pressure was 14.7 ± 5.1 mmHg, whilst postoperatively it was 14.2 ± 5.5 mmHg and 14.6 ± 4.3 mmHg at day 1 and day 7, respectively.

In three patients hypotony was found on the first day postoperatively, but intraocular pressure returned to normal within a week. There was no record of postoperative endophthalmitis or retinal detachment in any of the patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.